Skip to Main Content
HBS Home
  • About
  • Academic Programs
  • Alumni
  • Faculty & Research
  • Baker Library
  • Giving
  • Harvard Business Review
  • Initiatives
  • News
  • Recruit
  • Map / Directions
Faculty & Research
  • Faculty
  • Research
  • Featured Topics
  • Academic Units
  • …→
  • Harvard Business School→
  • Faculty & Research→
  • Research
    • Research
    • Publications
    • Global Research Centers
    • Case Development
    • Initiatives & Projects
    • Research Services
    • Seminars & Conferences
    →
  • Publications→

Publications

Publications

Filter Results: (610) Arrow Down
Filter Results: (610) Arrow Down Arrow Up

Show Results For

  • All HBS Web  (610)
    • People  (4)
    • News  (110)
    • Research  (426)
    • Events  (3)
    • Multimedia  (4)
  • Faculty Publications  (259)

Show Results For

  • All HBS Web  (610)
    • People  (4)
    • News  (110)
    • Research  (426)
    • Events  (3)
    • Multimedia  (4)
  • Faculty Publications  (259)
← Page 10 of 610 Results →

    Amy W. Schulman

    Amy W. Schulman joined Harvard Business School’s Faculty as a Senior Lecturer in July 2014.

    In addition to her responsibilities at Harvard, Ms. Schulman is a managing partner at Polaris Partners, who focuses on investing in healthcare... View Details

    • 09 May 2024
    • Research & Ideas

    Called Back to the Office? How You Benefit from Ideas You Didn't Know You Were Missing

    knowledge sharing outside one’s core department. That is one implication of a new study about how knowledge is shared that focuses on academia, but may offer lessons for technology, pharmaceutical development, and other STEM industries.... View Details
    Keywords: by Ben Rand
    • 21 Feb 2018
    • Research & Ideas

    When a Competitor Abandons the Market, Should You Advance or Retreat?

    Terminations: Learning from Competitors’ R&D Failures, Krieger explores how pharmaceutical companies choose to react strategically when a competitor exits the market during the development stage. These... View Details
    Keywords: by Rachel Layne; Pharmaceutical; Pharmaceutical
    • April 2009
    • Case

    GSK's Acquisition of Sirtris: Independence or Integration?

    By: Toby E. Stuart and James Weber
    An executive from pharmaceutical company GSK must choose how much to integrate a recently acquired biotechnology firm, Sirtris. Moncef Slaoui, GSK's global head of R&D, championed the acquisition of Sirtris to gain access to its potentially revolutionary science.... View Details
    Keywords: Mergers and Acquisitions; Resource Allocation; Organizational Change and Adaptation; Organizational Culture; Organizational Structure; Research and Development; Science-Based Business; Integration
    Citation
    Educators
    Purchase
    Related
    Stuart, Toby E., and James Weber. "GSK's Acquisition of Sirtris: Independence or Integration?" Harvard Business School Case 809-026, April 2009.
    • September 2007
    • Article

    Investigative Negotiation

    By: Deepak Malhotra and Max H. Bazerman
    This article includes a one-page preview that quickly summarizes the key ideas and provides an overview of how the concepts work in practice along with suggestions for further reading. Negotiators often fail to achieve results because they channel too much effort into... View Details
    Keywords: Knowledge Acquisition; Knowledge Use and Leverage; Negotiation Process; Negotiation Tactics; Motivation and Incentives; Perspective; Pharmaceutical Industry
    Citation
    Find at Harvard
    Purchase
    Related
    Malhotra, Deepak, and Max H. Bazerman. "Investigative Negotiation." Harvard Business Review 85, no. 9 (September 2007).
    • July 2023
    • Case

    HealthVerity: Real World Data and Evidence

    By: Satish Tadikonda
    Andrew Kress (CEO and founder) and his team had built a promising marketplace business at HealthVerity serving its core market in healthcare, with a focus on pharmaceutical R&D and services. Thus far, HealthVerity’s products had been unique to the pharma and pharma... View Details
    Keywords: Growth and Development Strategy; Market Entry and Exit; Product Marketing
    Citation
    Educators
    Purchase
    Related
    Tadikonda, Satish. "HealthVerity: Real World Data and Evidence." Harvard Business School Case 824-019, July 2023.
    • 11 Apr 2024
    • In Practice

    Why Progress on Immigration Might Soften Labor Pains

    Almost one-third of Americans consider immigration the most important “problem” that the United States faces, according to a new Gallup poll. And yet, companies say they need far more workers than the current system allows. Some business... View Details
    Keywords: by Rachel Layne
    • 27 Sep 2011
    • First Look

    First Look: September 27

    specificity at the individual level. We discuss the implications of our results for the study of learning and experience as well as for the providers and consumers of outsourced services. Download the paper: http://www.hbs.edu/research/pdf/11-057.pdf U.S. Healthcare... View Details
    Keywords: Sean Silverthorne
    • July 2001 (Revised August 2005)
    • Case

    Medicines Company, The

    By: John T. Gourville
    It is early 2001 and the Medicines Co. just received FDA approval to market Angiomax, a blood thinner to be used during angioplasties and heart procedures. It is intended to be a better alternative to Heparin, an 80-year-old drug that costs less then $10 per dose. The... View Details
    Keywords: Business Model; Change Management; Decision Choices and Conditions; Cost Management; Price; Product Marketing; Product Launch; Product Development; Risk and Uncertainty; Pharmaceutical Industry; Pharmaceutical Industry
    Citation
    Educators
    Purchase
    Related
    Gourville, John T. "Medicines Company, The." Harvard Business School Case 502-006, July 2001. (Revised August 2005.)
    • October 2012
    • Case

    GSK's Acquisition of Sirtris: Independence or Integration? (Abridged)

    By: Toby Stuart and James Weber
    An executive from pharmaceutical company GSK must choose how much to integrate a recently acquired biotechnology firm, Sirtris. Moncef Slaoui, GSK's global head of R&D, championed the acquisition of Sirtris to gain access to its potentially revolutionary science.... View Details
    Keywords: Mergers and Acquisitions; Resource Allocation; Organizational Change and Adaptation; Organizational Culture; Organizational Structure; Research and Development; Science-Based Business; Integration
    Citation
    Educators
    Purchase
    Related
    Stuart, Toby, and James Weber. "GSK's Acquisition of Sirtris: Independence or Integration? (Abridged)." Harvard Business School Case 813-028, October 2012.
    • May 2023 (Revised June 2023)
    • Supplement

    Novartis (C): Reimagining Medicine

    By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
    This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details
    Keywords: Health Testing and Trials; Health Care and Treatment; Business Model; Problems and Challenges; Pharmaceutical Industry; Switzerland
    Citation
    Related
    Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (C): Reimagining Medicine." Harvard Business School Supplement 723-445, May 2023. (Revised June 2023.)
    • Research Summary

    Current Research

    Ian studies extrinsic rewards -- monetary incentives from formal compensation systems, as well as other formal and informal external rewards-- in order to help businesses understand the tensions and tradeoffs inherent in motivating employees. His research takes a... View Details

    • October 2019
    • Supplement

    Impax Laboratories: Executing Accretive Transactions (A)

    By: Benjamin C. Esty and Daniel Fisher
    Impax Laboratories was a technology-based pharmaceutical company that used a “dual platform” strategy to sell both generic and branded treatments. While Impax had grown organically for most of its history, it was beginning to use major acquisitions for growth. In the... View Details
    Keywords: Financial Reporting; Financial Statements; Mergers and Acquisitions; Capital Structure; Financial Strategy; Competition; Competitive Advantage; Corporate Strategy; Pharmaceutical Industry; United States
    Citation
    Purchase
    Related
    Esty, Benjamin C., and Daniel Fisher. "Impax Laboratories: Executing Accretive Transactions (A)." Harvard Business School Spreadsheet Supplement 220-710, October 2019.
    • October 2019
    • Case

    Impax Laboratories: Executing Accretive Acquisitions (A)

    By: Benjamin C. Esty and Daniel Fisher
    Impax Laboratories was a technology-based pharmaceutical company that used a “dual platform” strategy to sell both generic and branded treatments. While Impax had grown organically for most of its history, it was beginning to use major acquisitions for growth. In the... View Details
    Keywords: Financial Reporting; Financial Statements; Mergers and Acquisitions; Capital Structure; Competition; Competitive Advantage; Corporate Strategy; Pharmaceutical Industry; United States
    Citation
    Educators
    Purchase
    Related
    Esty, Benjamin C., and Daniel Fisher. "Impax Laboratories: Executing Accretive Acquisitions (A)." Harvard Business School Case 220-030, October 2019.

      Incentives for Bad Science

      Randomized controlled trials (RCTs) inform medical practice, health care delivery, follow-on research, regulation, and health policy. Yet, many RCTs are inadequately randomized, blinded, and reported. To analyze scientists' and firms' incentives to meet clinical trial... View Details
      • Research Summary

      Multinational Enterprises and Corporate Responsibility

      By: Nien-he Hsieh

      Multinational enterprises, especially those operating in developing economies, face wide-ranging demands to help persons whose basic needs are unmet. Pharmaceutical companies, for example, are asked to provide access to life-saving therapies to patients in countries... View Details

      • April 2011 (Revised April 2015)
      • Case

      Cipla 2011

      By: Rohit Deshpande, Sandra J. Sucher and Laura Winig
      Dr. Yusuf Hamied, head of the Indian pharma and generics manufacturing company Cipla, is weighing options for how to continue to support the global fight against HIV/AIDS while positioning his company for growth in a changing regulatory landscape. View Details
      Keywords: Leadership; Leading Change; Leadership Style; Management Teams; Governance Compliance; Corporate Strategy; Pharmaceutical Industry
      Citation
      Educators
      Purchase
      Related
      Deshpande, Rohit, Sandra J. Sucher, and Laura Winig. "Cipla 2011." Harvard Business School Case 511-050, April 2011. (Revised April 2015.)

        Henry W. McGee

        Henry McGee joined the HBS faculty in 2013 after retiring as President of HBO Home Entertainment, the digital and DVD program distribution division of Home Box Office, the pioneering premium television company. A member of the Entrepreneurial Management Unit,... View Details

        Keywords: television; motion pictures; media; e-commerce industry; entertainment; broadcasting; distribution; health care; journalism; wholesale; arts; nonprofit industry

          Jay W. Lorsch

          Jay W. Lorsch is the Louis Kirstein Professor of Human Relations at the Harvard Business School. He is editor of View Details

            Michael Beer

            MICHAEL BEER

            Mike Beer is the Cahners-Rabb Professor of Business Administration, Emeritus at the Harvard Business School and author Fit to Compete: Why Honest Conversations About Your Company’s... View Details

            • ←
            • 10
            • 11
            • …
            • 30
            • 31
            • →
            ǁ
            Campus Map
            Harvard Business School
            Soldiers Field
            Boston, MA 02163
            →Map & Directions
            →More Contact Information
            • Make a Gift
            • Site Map
            • Jobs
            • Harvard University
            • Trademarks
            • Policies
            • Accessibility
            • Digital Accessibility
            Copyright © President & Fellows of Harvard College.